<DOC>
	<DOCNO>NCT02548936</DOCNO>
	<brief_summary>This randomize single-blind trial . This study aim determine intensive lipid-lowering therapy ( simvastatin-ezetimibe combination therapy ) could reduce progression atherosclerosis effectively safely among SLE patient carotid artery intima thickening . The study result expect helpful SLE patient prevent atherosclerosis .</brief_summary>
	<brief_title>Efficacy Safety Simvastatin-ezetimibe Combination Therapy Among Patients With SLE</brief_title>
	<detailed_description>Patient Registries : A convenient consecutive sampling use recruit participant outpatients department rheumatism PUMCH . Prior enrollment study , patient give write , informed consent . To minimize subject non-response rejection , investigator inform patient benefit risk , feedback physical examination result free recruit period . Randomization : A randomization use allocate patient Lipid-lowering treatment group control group . Blind : A trained ultrasonographer assess carotid intima medium thickness ( CIMT ) ( baseline 12 month ) blind clinical treatment information . Statistical analysis : The characteristic study sample summarize use descriptive statistic dichotomous ordinal data present percentage continuous data mean , standard deviation , median , interquartile range . Differences progression rate atherosclerosis intervention group control group assess either test non-parametric Wilcoxon test . A multivariable linear regression model use evaluate relationship progression CIMT intervention control confound factor . Statistical significance define 2-tailed P value less 0.05 . All calculation perform use SAS version 9.3 . Quality Control Data Management : Two doctor ( main investigator ) come department cardiology experience clinical trial data manager serve Data Safety Monitor . A monthly meeting set investigator monitor . The monitor need review study protocol set Data Safety Management plan recruitment . Then , need review rate recruitment , adherence , follow-up condition assess efficacy harm study . If Monitors find simvastatin-ezetimibe combination therapy cause severe adverse event , detail record need . Monitors need inform main investigator within 3 hour inform state China Food Drug Administration within 24 hour . Interim monitoring focus data quality , percentage AE SAE , evidence benefit .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1. age ≥18 year clinical diagnosis SLE 2. abnormal CIMT ( ≥0.9 mm site ) Bmode ultrasound 3 . LDLC≥100mg/dl 4. sign write informed consent able obtain . 1. atherosclerotic cardiovascular disease 2. diabetes 3. history intolerance allergy statins ezetimibe 4. ever receive statin ezetimibe within 12 month study entry 5 . LDLC≥190mg/dl 6. active infection 7 . ALT high 2 time upper normal limit CK high 1.5 time upper normal limit . 8. pregnant lactate woman 9. patient severe SLE .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Cholesterol , LDL</keyword>
	<keyword>Carotid Intima-Media Thickness</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Ezetimibe , Simvastatin Drug Combination</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
</DOC>